GE HealthCare's mangaciclanol Phase 2 results support move to Phase 3 MRI trial
GEHC•
GEHC•GE HealthCare said Phase 2 results support advancing mangaciclanol into Phase 3 of the LUMINA trial. The study met its primary endpoint, showing similar overall diagnostic preference to gadobutrol, with no safety concerns reported.
The Phase 2 study met its primary endpoint, showing similar overall diagnostic preference for investigational manganese-based MRI contrast agent mangaciclanol compared with gadobutrol. No safety concerns emerged following mangaciclanol administration.
The Phase 3 trial will further evaluate the agent’s efficacy and safety in detecting and characterizing central nervous system and body lesions. Mangaciclanol has FDA Fast Track designation but is not approved. Preliminary Phase 2 results are scheduled for presentation at RSNA in Chicago on December 1, 2026.
